Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
about
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Review article: Pathogenesis and management of gastric carcinoid tumours.From somatostatin to octreotide LAR: evolution of a somatostatin analogueMalignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature.Gastrointestinal neuroendocrine tumors.Treatment of liver metastases in patients with digestive neuroendocrine tumors.Octreotide therapy in dumping syndrome: Analysis of long-term results.Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.Treatment of ECL cell carcinoids with octreotide LAR.Hypercalcaemia caused by a carcinoid tumour.Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.Tumors of the Pancreatic Body and Tail.Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
P2860
Q24685837-12EED8FD-8791-4FA3-A4C0-9B6ADE9B2406Q30364864-61F7E0DC-22EC-4515-B823-E4C7C8D9D6A0Q35760798-6971231C-7DCC-4513-8496-3CB08EC887B2Q36632315-2D09B480-F47D-4927-919B-BC929E47E4DEQ36919554-1147AA4C-4168-477B-98C2-CE7CB741F489Q37682771-A91E14EB-1042-4760-9F91-D3070DB26137Q37799954-C8312591-71E2-4D45-A550-BB83E95B6855Q38029275-F8712788-A832-468F-8E73-B975100A6979Q39344385-D1387D59-D881-441F-AAC4-14769C801A68Q39372287-770A7F35-AFCD-446F-929F-973CE8360CD5Q45061296-930BD7EA-BF48-4729-9AC6-1CF1B27288B0Q45938294-890F9093-3E58-479D-A970-836D5FCB3ACFQ46789986-B2F96596-63BF-4712-BD33-3B0E7BB55E3EQ46946845-85A7CC0A-1550-40A7-B900-5FCE73ED5881Q47097042-638C10CF-C944-4956-A7AA-45772783FE37Q47944297-27536ABA-6CBB-4BB0-9E81-B76C9A3A21DC
P2860
Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Sandostatin LAR (long-acting o ...... syndrome: a 3-year experience.
@en
Sandostatin LAR
@nl
type
label
Sandostatin LAR (long-acting o ...... syndrome: a 3-year experience.
@en
Sandostatin LAR
@nl
prefLabel
Sandostatin LAR (long-acting o ...... syndrome: a 3-year experience.
@en
Sandostatin LAR
@nl
P2093
P2860
P1476
Sandostatin LAR (long-acting o ...... syndrome: a 3-year experience.
@en
P2093
Buscombe JR
Chapman MH
Reynolds N
P2860
P304
P356
10.1046/J.1365-2036.2003.01420.X
P407
P577
2003-02-01T00:00:00Z